In 2009, the Russian government formulated a strategy for the development of pharmaceutical industry, and made it clear that in the next 10 year, the domestic drug market share will reach 50%, the sales market share will reach 90%, the export volume of drugs will increase by 8 times, and the output of new drugs will increase by 1 times. After two years of development, the Russian government's medical support policy has achieved initial results. St Petersburg, Yekaterinburg, Kaluga, yaroslav and other places have established pharmaceutical industrial clusters and economic and technological development zones to attract foreign pharmaceutical enterprises to invest and build factories and carry out localized drug production. Novartis 20 10 set up a factory in Russia, with an estimated investment of 500 million US dollars in five years. The Russian pharmaceutical market has great development potential, and the Chinese and Russian pharmaceutical industries are highly complementary and have broad development prospects. However, if China pharmaceutical enterprises want to successfully enter the Russian pharmaceutical market and achieve sustained and stable development, they need to choose appropriate market development strategies and make good use of various opportunities and platforms. First of all, pharmaceutical companies should strengthen their confidence in market development, advance patiently and steadily, and don't rush for success. The Russian pharmaceutical market has long been monopolized by European and American pharmaceutical companies and products, and it will take some time for the market to understand China's pharmaceutical products. At the same time, due to the improper market competition strategy adopted by some Russian enterprises in the initial stage of opening up the Russian market, many Russians often have a negative understanding of the quality of China products, and there is speculation on the quality of individual drugs in China in the international market, so most China pharmaceutical brand enterprises and products are not recognized by the Russian market. It takes a long time for pharmaceutical enterprises in China to explore the market. Take Harbin Pharmaceutical Group as an example. On 200 1, Harbin pharmaceutical group registered the medical trademark of cefazolin sodium in Russia, becoming the first China pharmaceutical enterprise to successfully register in Russia. It was not until the beginning of 20 1 1 that the first pharmaceutical factory built by Harbin Pharmaceutical Group in Russia was officially put into production. Drug quality is related to the life and health of users, and ensuring drug quality is the social responsibility of every pharmaceutical enterprise. Pharmaceutical companies must adhere to the strategy of winning by quality, and must never expand the Russian market by the strategy of lowering quality at low prices. In the Russian pharmaceutical market, consumers and competitors have a strong sense of quality. 20 14 Russian pharmaceutical manufacturers will implement European quality standards. These factors require China enterprises interested in exploring the Russian pharmaceutical market to put drug quality first, improve the cost performance of China's pharmaceutical products and enhance their competitiveness in the Russian pharmaceutical market on the premise of ensuring quality. At present, the Russian pharmaceutical market is highly dependent on foreign pharmaceutical products, and the threshold for drug import is relatively low. China pharmaceutical enterprises should obtain the Russian medical market pass as soon as possible to gain the first-Mover advantage in the market. Because market development is a long process, with the adjustment of Russian national medicine strategy, the access policy of medical market will be tightened. In addition, the Russian pharmaceutical market contains many market opportunities, and China pharmaceutical enterprises can adopt flexible and diverse ways to realize product export or cooperation. In Russia, Russian enterprises can directly sell pharmaceutical raw materials to local growing pharmaceutical enterprises, or they can directly export pharmaceutical products by using their excellent cost performance. They can also seize the opportunity of developing local pharmaceutical enterprises in China and promote the export of raw materials and technologies through investment cooperation. China's traditional Chinese medicine health care products can be sold directly, or they can cooperate with local senior health clubs to promote products. According to reports, as the largest and most authoritative pharmaceutical import and export industry organization in China, the China Chamber of Commerce for Import and Export of Medicines and Health Products has supported companies such as Kunming Dianhong Pharmaceutical and Shenwei Pharmaceutical to successfully register 9 kinds of health products in Russia.